2024-2027

Cancedda L.

CARIPLO Giovani 2022 - Cancedda

The KCC2 interactome: A structural approach to provide mechanistic understanding of GABAergic inhibition and therapeutic venues for neurodevelopmental disorders

Foundation

2023-2025

Fadiga L., Cancedda L.

MOH PNRR-POC 2022 Fadiga_Cancedda

Brain Lesions Border Characterization: Intraoperative Electrophisiology and Off-line Neurobiology - BLBC

National

2022-2025

Gustincich S., Armirotti A., Athanassiou A., Barberis A., Cancedda L., Cavalli A., De Pietri Tonelli D., De Vivo M., Diaspro A., Girotto S., Grimaldi B., Netti P., Nicassio F., Petrini E., Pompa P.P., Ruocco G., Siciliano V., Tartaglia G.G., Tirelli N., Tonini R., Tucci V., Vicidomini G.

National Center for Gene Therapy and Drugs based on RNA Technology

National Center for Gene Therapy and Drugs based on RNA Technology

National

2022-2024

Cancedda L., Tucci V.

BuPra

Treatment of social, cognitive, and sleep impairment in a mouse model of Prader- Willi syndrome by repurposing of the FDA-approved diuretic Bumetanide.

Foundation Ended

2021-2024

Savardi A.

Lejeune 2021 Savardi

Early NKCC1 Inhibition to treat epilepsy and hyperactivity in Down syndrome

Foundation

2019-2021

Portioli C.

3D NKCC1

Interdisciplinary approach to characterize the structure and the ion transport mechanism of NKCC1, a key target for brain disorders.

European Ended

2017-2023

Cancedda L.

GenEdiDS

GenEdiDS: Rescuing Cognitive Deficits in Neurodevelopmental Disorders by Gene Editing in Brain Development: the case of Down Syndrome

European Ended

2016-2018

Cingolani L., Contestabile A.

SAN PAOLO 2015 CINGOLANI

Genome-editing approaches for personalized medicine in inherited diseases

Foundation Ended

2016-2021

Cancedda L.

DTI Cancedda

Targeting aberrant Cl‐ homeostasis and GABAergic transmission in Down syndrome to design innovative therapeutic approaches

In Kind Ended

2014-2017

Cancedda L.

CARIPLO 2013 CANCEDDA

Caratterizzazione fenotipica delle mutazioni di PCDH19 che causano la sindrome 'Epilessia e Ritardo Mentale Femminile (EFMR)' usando modelli in vitro ed in vivo

Foundation Ended

2014-2016

Cancedda L.

LEJEUNE 2014 CANCEDDA

Experimental and clinical evaluation of a clinically-used CI transporter inhibitor to rescue cognitive functions by reverting excitatory GABA in Down syndrome - Part of the study concerning Ts65Dn mice

Foundation Ended

2014-2015

Ghezzi D.

GOAP Ghezzi 2014

Gene editing to treat genetic photoreceptor degeneration

International Ended

2013-2017

Cancedda L.

Telethon 2013 Cancedda

Unravelling the Rett syndrome: effects of MeCP2 mutations on synaptic function

Foundation Ended

2012-2015

Contestabile A.

Lejeune 2012 Contestabile

Safe modulation of GABAergic signaling by a clinically-used inhibitor of chloride transporters to rescue cognitive functions in a mouse model of Down syndrome

Foundation Ended

2010-2014

Cancedda L.

TELETHON 2010 CANCEDDA

Role of GABAA-receptor mutations in idiopathic generalized epilepsy: a developmental study

Foundation Ended